Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem; Alberto Gil-Jimenez; Hamza Ali; Jeroen van Dorp; Nick van Dijk; Maurits L. van Montfoort; Maartje Alkemade; Annegien Broeks; Iris M. Seignette; Erik Hooijberg; Wim Brugman; Rhianne Voogd; Bas W.G. van Rhijn; Laura S. Mertens; Jeantine M. de Feijter; Niven Mehra; Antoine G. van der Heijden; Richard P. Meijer; Britt B.M. Suelmann; Wouter Scheper; Lodewyk F.A. Wessels; Daniël J. Vis; Michiel S. van der Heijden

doi:10.1158/1078-0432.30125707

Key Points

Tumor mutational burden (TMB) distinguishes responders from non-responders to ipilimumab and nivolumab.
In ipilimumab-high cohorts, TMB was observed to vary significantly between responders and non-responders.
Observational analysis showed distinct TMB patterns for patients in both ipilimumab-high and ipilimumab-low cohorts.
These findings highlight the potential role of TMB in predicting treatment outcomes for urothelial cancer.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Analysis highlights tumor mutational burden distinctions in urothelial cancer responders and non-responders, indicating treatment dynamics.

Abstract

Tumor mutational burden (TMB) in responders vs non-responders for ipilimumab-high and ipilimumab-low. Baseline TMB (somatic non-synonymous TMB per Mb) in the ipilimumab-high cohorts (cohort 1 and 2A; left panel) and the ipilimumab-low cohort (cohort 2B; right panel) for responders (blue; <=ypT1N0) and non-responders (orange; ypT2-4aNx or ypTxN1-3).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stockem et al. (2025) studied this question.

synapsesocial.com/papers/68d4538731b076d99fa58955 https://doi.org/10.1158/1078-0432.30125707

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading